Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B

Journal of Medical Virology

Volumn 79, Issue 9, 2007, Pages 1286-1292

  Arase, Yasuji ^a   Ikeda, Kenji ^a   Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Kobayashi, Masahiro ^a   Akuta, Norio ^a   Hosaka, Tetsuya ^a   Sezaki, Hitomi ^a   Yatsuji, Hiromi ^a   Kawamura, Yusuke ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis B; Hepatitis e antigen; Interferon; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

ADULT; AGE DISTRIBUTION; APPETITE DISORDER; ARTICLE; CHRONIC HEPATITIS; CONJUNCTIVITIS; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NONHUMAN; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; JAPAN; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

HEPATITIS B VIRUS; LETTUCE MOSAIC VIRUS;

EID: 34547098580     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20928     Document Type: Article

References (27)

1. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H. 2006. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 119:e9-e16.
2. Chen YC, Sheen IS, Chu CM, Liaw YF. 2002. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 123:1084-1089.
3. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. 2004. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 116:829-834.
4. De Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, Rumi MG, Donato MF, Ronchi G. 1993. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 118:191-194.
5. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520.
6. Di Bisceglie AM, Carithers RL, Jr., Gores GJ. 1998. Hepatocellular carcinoma. Hepatology 28:1161-1165.
7. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. EASL Jury. N Engl J Med 341:1256-1263.
8. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. 2003. Histological outcome during long-term lamivudine therapy. Gastroenterology 124:105-117.
9. EASL. 2003. International consensus conference on hepatitis B. 13-14 September 2002. Geneva, Switzerland, Consensus statement (long version). J Hepatol 38:533-540.
10. Harrington DP, Fleming TR. 1983. A class of rank test procedures for censored survival data. Biomedaica 62:205-209.
11. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. 2007. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 45:1056-1075.
12. Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S. 1999. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J Clin Microbiol 37:310-314.
13. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339:61-68.
14. Liaw YF, Tai DI, Chu CM, Chen TJ. 1988. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 8:493-496.
15. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. 1991. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 13:627-631.
16. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119: 172-180.
17. Liaw YF, Leung N, Guan R, Lau GK, Merican I. 2003. Asian-Pacific Consensus Working Parties on Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: An update. J Gastroenterol Hepatol 18:239-245.
18. Lok AS, McMahon BJ. Practice Guidelines Committee. American Association for the Study of Liver Disease (AASLD). 2004. Chronic hepatitis B: Update of recommendations. Hepatology 39:857-861.
19. McMahon BJ, Holck P, Bulkow L, Snowball M. 2001. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 135:759-768.
20. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334:1422-1427.
21. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M. 1999. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 80:97-112.
22. Viola LA, Barrison IG, Coleman JC, Paradinas FJ, Fluker JL, Evans BA, Murray-Lyon IM. 1981. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain. Lancet 2:1156-1159.
23. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312-323.
24. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ, Taiwan Community-Based Cancer Screening Project Group. 2002. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347:168-174.
25. Yim HJ, Lok AS. 2006. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 43:S173-S181.
26. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, Liaw YF. 1997. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 145:1039-1047.
27. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. 2004. HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. Hepatology 39: 1694-1701.